Dr Abhi Pal

Conjoint Senior Lecturer

BSc (Hons) MBBS FRACP PhD

Medicine & Health

School of Clinical Medicine

Dr Abhi Pal is a Staff Specialist Medical Oncologist at Liverpool Hospital and Bankstown Hospital. He has a clinical focus on early phase cancer clinical trials and thoracic malignancies. His research focus is on improving diversity in cancer clinical trials, and equity in cancer care, with a particular focus on multicultural communities and populations with a non English language preference.

Journal articles | 2026

Li JJ; Saab J; Bray V; Williamson J; Pal A; Yip PY; Ding P; Vinod SK; French B; Lee C; Gupta R; Cooper WA; Wang B; Lee CS, 2026, 'Histopathological associations, molecular findings and clinical outcomes of patients with non-small cell lung carcinoma with MET alterations: a 3-year retrospective Australian case series', Pathology, 58, pp. 41 - 51, http://dx.doi.org/10.1016/j.pathol.2025.07.009

Journal articles | 2025

Childs S; Nindra U; Shivasabesan G; Yoon R; Haider S; Hong M; Cooper A; Roohullah A; Wilkinson K; Chua W; Pal A, 2025, 'Social Characteristics of Culturally and Linguistically Diverse Cancer Patients Enrolled in Early Phase Clinical Trials in South Western Sydney', Oncology Switzerland, 103, pp. 219 - 226, http://dx.doi.org/10.1159/000540462

Journal articles | 2025

Grant SJ; Ouriques M; Pal A; Lee S; Challam S; Jasicki L, 2025, 'Improving Ethnic Diversity in Cancer Trials Through Healthcare Interpreter Training', Cancer Medicine, 14, http://dx.doi.org/10.1002/cam4.71071

Journal articles | 2025

Huang N; Descallar J; Vo S; Lee SS; Wilkinson K; Roohullah A; Cooper A; Bray V; Chua W; Ní Chróinín D; Pal A, 2025, 'Documentation of Advance Care Planning in Early Phase Cancer Clinical Trials: An Australian Single-Centre Experience', Cancers, 17, http://dx.doi.org/10.3390/cancers17223655

Journal articles | 2025

Lugowska IA; Simonelli M; Xue J; Sacher AG; Stathis A; Dziadziuszko R; Park JO; Moreno V; Yeh Y-M; Sendur MAN; Su HY-L; Caglevic C; Xu R-H; Perets R; Ahern ES; Pal A; Jemielita T; Molife LR; Choi YS; Rojas C, 2025, 'The KRAS G12C inhibitor MK-1084 for KRAS G12C–mutated advanced colorectal cancer (CRC): Results from KANDLELIT-001.', Journal of Clinical Oncology, 43, pp. 3508 - 3508, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.3508

Journal articles | 2025

Nguyen J; Battisti NML; Ní Chróinín D; Hong M; Nindra U; Hong JH; Zwieky W; Wilkinson K; Yoon R; Cooper A; Roohullah A; Ng W; Chua W; Pal A, 2025, 'Inclusion of Older Adults in Early-Phase Cancer Clinical Trials: Safety, Efficacy and a Way Forward', Drugs and Aging, 42, pp. 1143 - 1158, http://dx.doi.org/10.1007/s40266-025-01260-y

Journal articles | 2025

Nguyen JTT; Nindra U; Tang J; Hong JH; Zwieky W; Hong M; Killen A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech C; Chua W, 2025, '166P Measuring what matters: RECIST response does not predict HRQoL in early-phase trials', Annals of Oncology, 36, pp. S1812 - S1812, http://dx.doi.org/10.1016/j.annonc.2025.10.1003

Journal articles | 2025

Nindra U; Hong JH; Tang J; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase clinical trials.', Journal of Clinical Oncology, 43, pp. 11118 - 11118, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11118

Journal articles | 2025

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Assessing Patient-Reported Financial, Social, and Time Toxicity in Early-Phase Cancer Clinical Trials in Australia Through a Prospective Multicenter Nonrandomized Cohort Study', JCO Oncology Practice, 3, pp. 1 - 1, http://dx.doi.org/10.1200/OP-25-00412

Journal articles | 2025

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen A; Dubey P; Attaullah J; Scott G; Cooper A; Wilkinson K; Pal A; Teng C; Roohullah A; Wei J; Ng W; Lemech C; Chua W, 2025, 'Prospective assessment of health-related quality of life in early phase oncology clinical trials: PEARLER', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf108

Journal articles | 2025

Nindra U; Tang J; Hong JH; Descallar J; Hong M; Killen AJ; Cooper AJ; Wilkinson KJ; Pal A; Teng C; Roohullah A; Wei J; Ng WL; Lemech CR; Chua W, 2025, 'Financial, social and time toxicity in early-phase cancer clinical trials: The PEARLER study.', Journal of Clinical Oncology, 43, pp. 11119 - 11119, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.11119

Journal articles | 2025

Nindra U; Tang J; Hong JH; Hong M; Teng C; Wei J; Killen A; Cooper A; Wilkinson K; Ng W; Lemech C; Chua W; Pal A, 2025, 'Evaluating patient diversity in early phase clinical trials in Australia through a prospective multicenter nonrandomized cohort study', Jnci Cancer Spectrum, 9, http://dx.doi.org/10.1093/jncics/pkaf035

Journal articles | 2025

Shahnam A; Davis A; Brown LJ; Sullivan I; Lin K; Ng C; Yeo N; Kong BY; Khoo T; Warburton L; Da Silva IP; Mullally W; Xu W; O'Byrne K; Bray V; Pal A; Mersaides A; Itchins M; Arulananda S; Nagrial A; Kao S; Alexander M; Lee CK; Solomon B; John T, 2025, 'Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations', Lung Cancer, 201, http://dx.doi.org/10.1016/j.lungcan.2025.108421

Journal articles | 2025

Xue J; Lugowska I; Simonelli M; Sacher AG; Stathis A; Dziadziuszko R; Park JO; Garcia VM; Yeh Y-M; Sendur MAN; Su Y-L; Caglevic C; Xu R-H; Perets R; Ahern ES; Pal A; Jemielita T; Molife RL; Choi SY; Rojas CI, 2025, '198MO MK-1084 for KRAS G12C-mutated advanced colorectal cancer (CRC): Updated findings from KANDLELIT-001', Annals of Oncology, 36, pp. S1822 - S1823, http://dx.doi.org/10.1016/j.annonc.2025.10.021

Journal articles | 2025

Young AL; McEnallay M; Day F; Vinod SK; Stone E; Morris S; Stefanovska E; Devitt B; Yip PY; Kukard C; Pal A; Thawal V; Wright G; Hofman A; Sareen H; McLennan J; Wong SO; Rubio C; Liu J; Smith A; Betts D; Mack J; Donnelly J; Barker D; Paul C, 2025, 'A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping Smoking', Asia Pacific Journal of Clinical Oncology, 21, pp. 368 - 376, http://dx.doi.org/10.1111/ajco.14153

Journal articles | 2025

Young AL; McEnallay M; Day F; Vinod SK; Stone E; Morris S; Stefanovska E; Devitt B; Yip PY; Kukard C; Pal A; Thawal V; Wright G; Hofman A; Sareen H; McLennan J; Wong SO; Rubio C; Liu J; Smith A; Betts D; Mack J; Donnelly J; Paul C, 2025, 'Smoking Cessation Practices in Australian Oncology Settings: A Cross-Sectional Study of Who, How, and When', Asia Pacific Journal of Clinical Oncology, 21, pp. 290 - 299, http://dx.doi.org/10.1111/ajco.14148

Journal articles | 2024

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Journal articles | 2024

Lugowska IA; Rojas C; Stathis A; Weindler S; Pal A; Alvarez EC; Mackiewicz J; Garrido M; Sendur MAN; Lakhani NJ; Frentzas S; Dziadziuszko R; Sacher AG; Wakuda K; Kato T; Perets R; Fernandez OOC; Jemielita T; Choi Y; Juergens RA, 2024, 'A phase 1, open-label, multicenter study evaluating MK-1084 as monotherapy and in combination with other therapies in patients with KRAS G12C mutant advanced solid tumors', Journal of Clinical Oncology, 42, http://dx.doi.org/10.1200/JCO.2024.42.3_suppl.TPS232

Journal articles | 2024

McNamee N; Harvey C; Gray L; Khoo T; Lingam L; Zhang B; Nindra U; Yip PY; Pal A; Clay T; Arulananda S; Itchins M; Pavlakis N; Kao S; Bowyer S; Chin V; Warburton L; Pires da Silva I; John T; Solomon B; Alexander M; Nagrial A, 2024, 'Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma—RIOMeso', Journal of Thoracic Oncology, 19, pp. 636 - 642, http://dx.doi.org/10.1016/j.jtho.2023.11.014

Journal articles | 2024

Nindra U; Bray V; Karikios D; Shafiei M; Subramaniam S; Ding P; Kao S; Pal A, 2024, 'Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical Oncologists', Oncology Switzerland, 102, pp. 732 - 736, http://dx.doi.org/10.1159/000535855

Journal articles | 2024

Nindra U; Pal A; Bray V; Yip PY; Tognela A; Roberts TL; Becker TM; Williamson J; Farzin M; Li JJ; Lea V; Hagelamin A; Ng W; Wang B; Lee CS; Chua W, 2024, 'Utility of multigene panel next-generation sequencing in routine clinical practice for identifying genomic alterations in newly diagnosed metastatic nonsmall cell lung cancer', Internal Medicine Journal, 54, pp. 596 - 601, http://dx.doi.org/10.1111/imj.16224

Journal articles | 2024

Pal A; Moussa RS; Smith B; Brady B; Karikios D; Boyle F; Chua W, 2024, 'Structural racism and inequity in cancer clinical trial participation: Time for solutions', Jnci Cancer Spectrum, 8, http://dx.doi.org/10.1093/jncics/pkae089

Journal articles | 2024

Rojas CI; Lugowska I; Juergens R; Sacher A; Weindler S; Sendur MAN; Dziadziuszko R; Pal A; Alvarez EC; Ahern ES; Lakhani N; Chen L; Jemielita T; Choi SY; Stathis A, 2024, '44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC', ESMO Open, 9, pp. 102273 - 102273, http://dx.doi.org/10.1016/j.esmoop.2024.102273

Journal articles | 2024

Whitaker KL; Cox A; McErlean G; Pal A; Stansbury K; Estupiñán Fdez De Mesa M; Kerrison RS; Gil N; Marcu A; Armes J; Yap ML; Delaney GP; Hoyo C; Pal A, 2024, 'Integrating Implementation Theory to Address Inequities in Cancer Care: Perspectives from an International Working Group', European Journal of Cancer Care, 2024, http://dx.doi.org/10.1155/2024/9994508

Journal articles | 2023

Nindra U; Pal A; Lea V; Lim SHS; Wilkinson K; Asghari R; Roberts TL; Becker TM; Farzin M; Rutland T; Lee M; MacKenzie S; Ng W; Wang B; Soon Lee C; Chua W, 2023, 'Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population', Plos One, 18, http://dx.doi.org/10.1371/journal.pone.0292087

Journal articles | 2023

Nindra U; Pal A; Lee CS, 2023, 'Precision medicine in Australia: now is the time to get it right', Medical Journal of Australia, 218, pp. 330, http://dx.doi.org/10.5694/mja2.51887

Journal articles | 2023

Pal A; Daly R; Stapleton S; Yap C; Hong M; Grochot R; MohamedKhan S; Lai-Kwon JE; Magkos D; Rao Baikady B; Minchom AR; Banerji U; De Bono JS; Karikios DJ; Boyle FM; Lopez JS, 2023, 'CONSENT: Randomized controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials.', Journal of Clinical Oncology, 41, pp. 6560 - 6560, http://dx.doi.org/10.1200/jco.2023.41.16_suppl.6560

Journal articles | 2023

Rojas C; Lugowska I; Juergens R; Sacher A; Weindler S; Sendur MAN; Dziadziuszko R; Pal A; Castanon Alvarez E; Ahern ES; Lakhani N; Chen L-C; Jemielita T; Choi YS; Stathis A, 2023, '663P Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC', Annals of Oncology, 34, pp. S466 - S467, http://dx.doi.org/10.1016/j.annonc.2023.09.1849

Journal articles | 2022

Nindra U; Shahnam A; Stevens SX; Pal A; Yip PY; Adam T; Lee JHJ; Boyer MJ; Nagrial A; Kao SC-H; Bray VJ, 2022, 'The prognostic influence of neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in stage III non-small cell lung cancer (NSCLC) treated with consolidation durvalumab.', Journal of Clinical Oncology, 40, pp. e18773 - e18773, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18773

Journal articles | 2022

Nindra U; Stevens SX; Shahnam A; Pal A; Adam T; Yip PY; Lee JHJ; Boyer MJ; Nagrial A; Kao SC-H; Bray VJ, 2022, 'The influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.', Journal of Clinical Oncology, 40, pp. e18810 - e18810, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18810

Journal articles | 2022

Pal A; Daly R; Mohamedkhan S; Grochot R; Stapleton S; Yap C; Magkos D; Baikady BR; Minchom A; Banerji U; De Bono J; Karikios D; Boyle F; Lopez J, 2022, 'CONSENT - A Randomised Controlled Trial of Enhanced Informed Consent Compared to Standard Informed Consent to Improve Patient Understanding of Early Phase Oncology Clinical Trials – GBM Cohort (Nonrandomised) Analysis', Neuro-Oncology, 24, pp. iv14 - iv14, http://dx.doi.org/10.1093/neuonc/noac200.060

Journal articles | 2022

Papadatos-Pastos D; Yuan W; Pal A; Crespo M; Ferreira A; Gurel B; Prout T; Ameratunga M; Chénard-Poirier M; Curcean A; Bertan C; Baker C; Miranda S; Masrour N; Chen W; Pereira R; Figueiredo I; Morilla R; Jenkins B; Zachariou A; Riisnaes R; Parmar M; Turner A; Carreira S; Yap C; Brown R; Tunariu N; Banerji U; Lopez J; De Bono J; Minchom A, 2022, 'Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors', Journal for Immunotherapy of Cancer, 10, http://dx.doi.org/10.1136/jitc-2022-004495

Journal articles | 2022

Stapleton SE; Darlington AS; Minchom A; Pal A; Raynaud F; Wiseman T, 2022, 'Assessing cognitive toxicity in early phase trials - What are we missing?', Psycho Oncology, 31, pp. 405 - 415, http://dx.doi.org/10.1002/pon.5834

Journal articles | 2022

Stevens S; Nindra U; Shahnam A; Bray V; Pal A; Yip PY; Adam T; Nagrial A; Lee JH; Boyer M; Kao SC-H, 2022, '965P Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre, Australian experience', Annals of Oncology, 33, pp. S989 - S989, http://dx.doi.org/10.1016/j.annonc.2022.07.1091

Journal articles | 2021

Biondo A; Pal A; Riisnaes R; Shinde R; Tiu C; Lockie F; Baker C; Bertan C; Crespo M; Ferreira A; Pereira R; Figueiredo I; Miranda S; Gurel B; Carreira S; Banerji U; de Bono J; Lopez J; Tunariu N; Minchom A, 2021, 'Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation – a Single Unit Experience', Cancer Treatment and Research Communications, 27, http://dx.doi.org/10.1016/j.ctarc.2021.100309

Journal articles | 2021

Lai-Kwon J; Tiu C; Pal A; Khurana S; Minchom A, 2021, 'Moving beyond epidermal growth factor receptor resistance in metastatic non-small cell lung cancer - a drug development perspective', Critical Reviews in Oncology Hematology, 159, http://dx.doi.org/10.1016/j.critrevonc.2021.103225

Journal articles | 2021

Pal A; Shinde R; Miralles MS; Workman P; de Bono J, 2021, 'Applications of liquid biopsy in the Pharmacological Audit Trail for anticancer drug development', Nature Reviews Clinical Oncology, 18, pp. 454 - 467, http://dx.doi.org/10.1038/s41571-021-00489-x

Journal articles | 2021

Tiu C; Shinde R; Pal A; Biondo A; Lee A; Tunariu N; Jhanji S; Grover V; Tatham K; Gruber P; Banerji U; De Bono JS; Nicholson E; Minchom AR; Lopez JS, 2021, 'A wolf in sheep’s clothing: Systemic immune activation post immunotherapy', Journal of Immunotherapy and Precision Oncology, 4, pp. 189 - 195, http://dx.doi.org/10.36401/JIPO-21-9

Journal articles | 2021

Welti J; Sharp A; Brooks N; Yuan W; McNair C; Chand SN; Pal A; Figueiredo I; Riisnaes R; Gurel B; Rekowski J; Bogdan D; West W; Young B; Raja M; Prosser A; Lane J; Thomson S; Worthington J; Onions S; Shannon J; Paoletta S; Brown R; Smyth D; Harbottle GW; Gil VS; Miranda S; Crespo M; Ferreira A; Pereira R; Tunariu N; Carreira S; Neeb AJ; Ning J; Swain A; Taddei D; Schiewer MJ; Knudsen KE; Pegg N; de Bono JS, 2021, 'Targeting the p300/cbp axis in lethal prostate cancer', Cancer Discovery, 11, pp. 1118 - 1137, http://dx.doi.org/10.1158/2159-8290.CD-20-0751

Journal articles | 2017

Rivalland G; Kao SC-H; Pavlakis N; Hughes BGM; Thapa B; Pal A; Walkiewicz M; Zimet AS; White S; O'Byrne K; Mitchell P; John T, 2017, 'Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression.', Journal of Clinical Oncology, 35, pp. 8514 - 8514, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.8514
Conference Abstracts | 2025

Simonelli M; Rojas CI; Dziadziuszko R; Park JO; Xue J; Felip E; Garcia VM; Bar J; Lakhani N; Kwiatkowski M; Ahern ES; Lee J; Joerger M; Stathis A; Pal A; Dizdar O; Jemielita T; Choi SY; Molife RL; Sacher A, 2025, 'monotherapy in participants (Pts) with KRAS G12C-mutated advanced solid tumors: Activity and safety in the phase I KANDLELIT-001 study', in ANNALS OF ONCOLOGY, ELSEVIER, GERMANY, Berlin, Vol. 36, presented at Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), GERMANY, Berlin, 17 October 2025 - 21 October 2025, http://dx.doi.org/10.1016/j.annonc.2025.08.1495

Preprints | 2024

Chauhan A; Chitkara U; Walsan R; Sansom-Daly UM; Manias E; Seah D; Dalli A; Challam S; El-Kabbout N; Tieu T; Sarwar M; Faiz M; Huang N; Rocha V; Pal A; Harrison R, 2024, Co-designing strategies to improve advance care planning among people from culturally and linguistically diverse backgrounds with cancer: iCanCarePlan study protocol, http://dx.doi.org/10.21203/rs.3.rs-3854846/v1

Vinod S, Khoo A, Berry M, Bell K, Ahmed E, Campisi J, Gollon C, Pal A, Seto SK, Tcharkhedian E, Tran T, Bray V. Implementation and evaluation of a geriatric-oncology model of care for older adults with lung cancer. J Geriatr Oncol. 2023 Jul 6:101578. doi: 10.1016/j.jgo.2023.101578. Epub ahead of print. PMID: 37422350. Nindra Letter

Nindra, U., Pal, A. and Lee, C.S. (2023), Precision medicine in Australia: now is the time to get it right. Med J Aust, 218: 330-330. https://doi.org/10.5694/mja2.51887

Nindra U, Shahnam A, Stevens S, Pal A, Nagrial A, Lee J, Yip PY, Adam T, Boyer M, Kao S, Bray V. Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia Pac J Clin Oncol. 2023 Feb 28. doi: 10.1111/ajco.13940. Epub ahead of print. PMID: 36855021.

Nindra U, Shahnam A, Stevens S, Pal A, Nagrial A, Lee J, Yip PY, Adam T, Boyer M, Kao S, Bray V. Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumab. Thorac Cancer. 2022 Nov;13(21):3058-3062. doi: 10.1111/1759-7714.14646. Epub 2022 Sep 16. PMID: 36111516; PMCID: PMC9626316.

Nindra, Udit, Jun Hee Hong, Bavanthi Balakrishnar, Abhijit Pal, and Wei Chua. "Review of Toxicities of Parp Inhibitors in Metastatic Castrate Resistant Prostate Cancer." Clinical Genitourinary Cancer (2022).

Papadatos-Pastos, Dionysis, Wei Yuan, Abhijit Pal, Mateus Crespo, Ana Ferreira, Bora Gurel, Toby Prout, et al. "Phase 1, Dose-Escalation Study of Guadecitabine (Sgi-110) in Combination with Pembrolizumab in Patients with Solid Tumors." Journal for ImmunoTherapy of Cancer 10, no. 6 (2022): e004495.

Stapleton, Sarah E., Anne‐Sophie Darlington, Anna Minchom, Abhijit Pal, Florence Raynaud, and Theresa Wiseman. "Assessing Cognitive Toxicity in Early Phase Trials‐What Are We Missing?". Psycho‐Oncology 31, no. 3 (2022): 405-15.

Tiu, Crescens, Rajiv Shinde, Abhijit Pal, Andrea Biondo, Alex Lee, Nina Tunariu, Shaman Jhanji, et al. "A Wolf in Sheep's Clothing: Systemic Immune Activation Post Immunotherapy." Journal of Immunotherapy and Precision Oncology 4, no. 4 (2021): 189-95.

Welti, Jonathan, Adam Sharp, Nigel Brooks, Wei Yuan, Christopher McNair, Saswati N. Chand, Abhijit Pal, et al. "Targeting P300/Cbp Axis in Lethal Prostate Cancer." Cancer Discovery (2021).

Pal, Abhijit, Sarah Stapleton, Christina Yap, Julia Lai-Kwon, Robert Daly, Dimitrios Magkos, Bindumalini Rao Baikady, et al. "Study Protocol for a Randomised Controlled Trial of Enhanced Informed Consent Compared to Standard Informed Consent to Improve Patient Understanding of Early Phase Oncology Clinical Trials (Consent)." British Medical Journal Open 11, no. 9 (2021): e049217.

Pal, Abhijit*, Rajiv Shinde*, Manuel Selvi Miralles, Paul Workman, and Johann de Bono. "Applications of Liquid Biopsy in the Pharmacological Audit Trail for Anticancer Drug Development." Nature Reviews Clinical Oncology 18, no. 7 (2021): 454-67. (* - co first author)

Biondo, Andrea*, Abhijit Pal*, Ruth Riisnaes, Rajiv Shinde, Crescens Tiu, Fran Lockie, Chloe Baker, et al. "Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation–a Single Unit Experience." Cancer Treatment and Research Communications 27 (2021): 100309. (* - co first author)

Lai-Kwon, Julia, Crescens Tiu, Abhijit Pal, Sachin Khurana, and Anna Minchom. "Moving Beyond Epidermal Growth Factor Receptor Resistance in Metastatic Non-Small Cell Lung Cancer-a Drug Development Perspective." Critical Reviews in Oncology/Hematology 159 (2021): 103225.

Ahmadzada, Tamkin, Wendy A. Cooper, Mikaela Holmes, Annabelle Mahar, Helen Westman, Anthony J. Gill, Ina Nordman, Po Yee Yip, Abhijit Pal, Rob Zielinski, Nick Pavlakis, Adnan Nagrial, Dariush Daneshvar, Daniel Brungs, Deme Karikios, Vesna Aleksova, Juliet Burn, Rebecca Asher, Georges E. Grau, Elham Hosseini-Beheshti, Glen Reid, Stephen Clarke, and Steven Kao. "Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population." JTO Clinical and Research Reports 1, no. 4 (2020): 100075.

Pal, Abhijit, Eugene Moylan, and Wei Chua. "Is It Time to Reconsider ‘Routine’ blood Tests in the Hospital Inpatient Setting?". Internal Medicine Journal 49, no. 12 (2019): 1554-55.

Sheikh, Mohamud, Shu Wang, Abhijit Pal, C. Raina MacIntyre, Nicholas Wood, and Hasantha Gunesekera. "Vitamin D Deficiency in Refugee Children from Conflict Zones." Journal of Immigrant and Minority Health 13, no. 1 (2011): 87-93.

Sheikh, Mohamud, Abhijit Pal, Shu Wang, C. Raina MacIntyre, Nicholas J. Wood, David Isaacs, Hasantha Gunasekera, et al. "The Epidemiology of Health Conditions of Newly Arrived Refugee Children: A Review of Patients Attending a Specialist Health Clinic in Sydney." Journal of Paediatrics and Child Health 45, no. 9 (2009): 509-13.

Follow

Dr Abhi Pal